4 May 2016

Verona to present clinical data on RPL554 at the ATS International Conference

04 May 2016, Cardiff – Verona Pharma plc (AIM: VRP.L), the drug development company focused on first- in-class medicines to treat respiratory diseases, today announces that it will present three abstracts at the American Thoracic Society (ATS) 2016 International Conference in San Francisco, USA between 13-18 May. The abstracts will cover clinical data related to the Company's lead drug RPL554, a novel inhaled PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties, currently in development as a nebulised treatment for acute exacerbations in chronic obstructive pulmonary disease (COPD) patients in a hospital or home-care setting.

All three posters support Verona Pharma's view that RPL554 could become an important, novel and complementary inhaled medicine for the treatment of respiratory diseases such as COPD, asthma, and cystic fibrosis.

All abstracts and details on timings can be accessed through the ATS website:

http://conference.thoracic.org/

Abstract ID 13130

Authors: L. Bjermer, J. Stewart, K. Abbott-Banner, K. Newman

Title: RPL554, a First-In-Class Dual Phosphodiesterase (PDE)3/4 Inhibitor, Is Equi-Effective as a Bronchodilator to Maximal Doses of Salbutamol in Asthmatics but with Fewer Adverse

Day/Date: SUNDAY, MAY 15, 2016

Location: Area A (Hall D) Moscone Centre (North Building) P36

Time: 9:00 AM-4:15 PM

Session: A31 - ASTHMA THERAPY: GLUCOCORTICOIDS AND BEYOND

Session Type: Thematic Poster Session

Abstract ID 6811

Authors: D. Singh, K.H. Abbott-Banner, F. Reid, K. Newman

Title: A Phase I, Randomised, Double Blind, Placebo Controlled, Study To Assess The Safety, Tolerability And Pharmacokinetics Of Multiple Inhaled Doses Of RPL554 Administered By Nebuliser To Healthy Male Subjects And Stable COPD Patients

Day/Date: WEDNESDAY, MAY 18, 2016

Location: Area A (Hall D) Moscone Centre (North Building) P71

Time: 9:00 AM-3:30 PM

Session :D37-COPD: DEVELOPMENTAL THERAPEUTICS

Session Type: Thematic Poster Session

Abstract ID 4841

Authors: D. Singh, K.H. Abbott-Banner, F. Reid, K. Newman

Title: A Phase I, Randomised, Double Blind, Placebo Controlled, Study To Assess The Safety, Tolerability And Pharmacokinetics Of Single Inhaled Doses Of The Dual Phosphodiesterase 3/4 (PDE3/4) Inhibitor RPL554 Administered By Nebuliser To Healthy Male subjects

Day/Date: WEDNESDAY, MAY 18, 2016

Location: Area A (Hall D) Moscone Centre (North Building) P72

Time: 9:00 AM-3:30 PM

Session: D37-COPD: DEVELOPMENTAL THERAPEUTICS

Session Type: Thematic Poster Session

For further information please contact: Verona Pharma plc

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com

About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. RPL554 has also shown anti-inflammatory effects and been well tolerated in clinical trials. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

Forward Looking Statements
This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the development of DPI and MDI formulations of RPL554 and the potential for these formulations to increase the market opportunity for the product, if approved.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
